Second generation ALK inhibitors in non-small cell lung cancer: Systemic review;Inhibiteurs de ALK de 2e génération dans le cancer bronchique non a petites cellules : revue de la literature

Bulletin du Cancer

Volumn 102, Issue 4, 2015, Pages 381-389

  Viala, Marie ^a   Brosseau, Solenn ^b   Planchard, David ^c   Besse, Benjamin ^d   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; ALECTINIB; CARBAZOLE DERIVATIVE; CERITINIB; CRIZOTINIB; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; ORGANOPHOSPHORUS COMPOUND; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONE; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE;

ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; NON SMALL CELL LUNG CANCER; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; PHASE 3 CLINICAL TRIAL (TOPIC);

CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; ORGANOPHOSPHORUS COMPOUNDS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 84930902409     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1016/j.bulcan.2015.02.016     Document Type: Review

References (42)

1. Soda M, et al. Identification of the transform-ing EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
2. Blackhall F, et al. Biomarkers. Ann Oncol 2012;23:ix73-94
3. Shaw AT, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53
4. Gainor JF, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer. Clin Cancer Res 2013;19:4273-81
5. Lindeman NI, et al. Molecular testing guide-line for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-59
6. Camidge DR, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrange-ments potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-90
7. Kwak EL, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703
8. Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs 2010;11:1477-90
9. Camidge DR, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-9
10. Shaw AT, et al. Crizotinib versus chemother-Apy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
11. Solomon. et al. First-line crizotinib versus che-motherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77
12. Costa DB, et al. Clinical experience with crizotinib in patients with advanced ALK-rear-ranged non-small-cell lung cancer and brain metastases. J Clin Oncol 2015. http://dx.doi. org/10.1200/JCO. 2014.59.0539
13. Kaneda H, et al. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer. J Thorac Oncol 2013;8(4):e32-3
14. Costa DB, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizoti-nib. J Clin Oncol 2011;29:e443-5
15. Camidge DR, Doebele RC. Treating ALK-posi-tive lung cancer-early successes and future challenges. Nat Rev Clin Oncol 2012;9:268-77
16. Perez CA, Velez M, Raez LE, Santos ES. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer har-boring EML4/ALK translocation. Lung Cancer 2014;84:110-5
17. Choi YL, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9
18. Doebele RC, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rear-ranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82
19. Katayama R, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012;4(120):120ra17
20. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol 2013;31:1105-11
21. Shaw AT, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97
22. Zykadia. http://www.pharma.us.novartis. com/product/pi/pdf
23. Shaw A, et al. Evaluation of ceritinib-treated patients (pts) with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases-in-The-ASCEND-1-study. Ann Oncol 2014;25(Suppl. 4):iv426-70 [10.1093]
24. Shaw A, et al. Two phase III studies evaluat-ing ceritinib in patients with anaplastic lym-phoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 and ASCEND-5. Ann Oncol 2014;25:iv469
25. Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H. Selective ALK inhibitor alectinib with potent antitumor activity in models of cri-zotinib resistance. Cancer Lett 2014;351:215-21
26. Sakamoto H, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679-90
27. Iwama E, et al. Development of anaplastic lymphoma kinase (ALK) inhibitors and mole-cular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014;7:375-85. http://dx.doi.org/10.2147/OTT.S38868
28. Ignatius Ou S-H, et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014;9:549-53
29. Seto T, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-Arm, open-label, phase 1-2 study. Lan-cet Oncol 2013;14:590-8
30. Gadgeel SM, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resis-tant ALK-rearranged non-small-cell lung can-cer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28
31. Zhou C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, rando-mised, phase 3 study. Lancet Oncol 2011;12 (8):735-42. http://dx.doi.org/10.1016/S1470-2045(11)70184-X
32. Rosell R, et al. Erlotinib versus standard che-motherapy as first-line treatment for Eur-opean patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, rando-mised phase 3 trial. Lancet Oncol 2012;13 (3):239-46. http://dx.doi.org/10.1016/S1470-2045(11)70393-X
33. Solomon B, Wilner KD, Shaw AT. Current status of targeted therapy for anaplastic lym-phoma kinase-rearranged non-small cell lung cancer. Clin Pharmacol Ther 2014;95:15-23
34. Camidge DR, et al. First-in-human dose-find-ing study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results. J Clin Oncol 2013;31
35. Esfahani K, Agulnik JS, Cohen V. A systemic review of resistance mechanisms and ongoing clinical trials in ALK-rearranged non-small cell lung cancer. Front Oncol 2014;4:174
36. Ou S-HI, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014;25:415-22
37. Felip E, et al. Efficacy and safety of ceritinib in patients with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC). An update of ASCEND-1. Ann Oncol 2014;25(Suppl. 4): iv455-56
38. Kim S, et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol 2013;8:415-22
39. Friboulet L, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4:662-73
40. Patnaik APA. Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial. J Clin Oncol 2013;31(Suppl. 11) [Abstr.2602]
41. A phase I/IIa open-label, dose escalation and cohort expansion trial of oral TSR-011 in patients with advanced solid tumors and lym-phomas. http://www.clinicaltrials.gov
42. Lovly CM, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011;71:4920-31